RWD110 Real World Outcomes in Patients with Advanced/Metastatic Solid Tumors Who Are Immuno-Oncology (IO) Naive and Received Second-Line Therapy: Analysis by Tumor Mutational Burden (TMB) Status
Abstract
Authors
A Gogate J Palaia Y Zhang M You A Sama